| Indicators | Browse All

NeOnc Technologies Holdings, Inc. (NTHI)

Healthcare | Biotechnology | Calabasas, United States | NasdaqGM
4.32 USD -0.17 (-3.786%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:21 a.m. EDT

The immediate outlook is deeply bearish as the stock trades significantly below its 50-day and 200-day moving averages, indicating persistent selling pressure and a lack of technical support. While recent headlines highlight clinical progress in CNS cancer programs and regulatory approvals in the UAE, these operational milestones are currently overshadowed by severe financial distress. The company is burning through cash rapidly, with operating cash flow at -$21.7 million and free cash flow at -$1.6 million, while holding negative book value and a precarious current ratio of 0.129. This liquidity crunch suggests the business may struggle to fund operations without further dilution or financing, regardless of pipeline success. Furthermore, the absence of any dividend history confirms this is a pure speculative vehicle with no income component. Investors should view the current price as a reflection of high risk rather than a bargain, given the deteriorating balance sheet and the market's skepticism about the company's ability to survive long enough to capitalize on its drug developments.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.105203
AutoTheta0.119752
AutoETS0.119867
AutoARIMA0.119869
MSTL_400.164545

Forecast horizon: 60 days | Selected: MSTL

Forecast Reliability
Score 33%
H-stat 1.12
Ljung-Box p 0.000
Jarque-Bera p 0.142
Excess Kurtosis 0.28
Attribute Value
Sector Healthcare
Market Cap 112,025,656
Forward P/E -5.73
Website https://www.neonc.com

Info Dump

Attribute Value
52 Week Change 0.10864198
Address1 23,975 Park Sorrento
Address2 Suite 205
All Time High 25.0
All Time Low 3.2
Ask 4.34
Ask Size 1
Average Daily Volume10 Day 59,560
Average Daily Volume3 Month 92,432
Average Volume 92,432
Average Volume10Days 59,560
Bid 4.32
Bid Size 1
Book Value -0.548
City Calabasas
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 4.32
Current Ratio 0.129
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 4.59
Day Low 4.31
Display Name NeOnc
Earnings Timestamp 1,779,107,400
Earnings Timestamp End 1,786,710,600
Earnings Timestamp Start 1,786,710,600
Ebitda Margins 0.0
Enterprise Value 109,573,288
Eps Current Year -0.85
Eps Forward -0.75333
Eps Trailing Twelve Months -1.73
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.835
Fifty Day Average Change -0.51499987
Fifty Day Average Change Percent -0.10651497
Fifty Two Week Change Percent 10.864199
Fifty Two Week High 12.99
Fifty Two Week High Change -8.67
Fifty Two Week High Change Percent -0.6674365
Fifty Two Week Low 3.69
Fifty Two Week Low Change 0.6300001
Fifty Two Week Low Change Percent 0.17073174
Fifty Two Week Range 3.69 - 12.99
Financial Currency USD
First Trade Date Milliseconds 1,742,995,800,000
Float Shares 8,882,177
Forward Eps -0.75333
Forward P E -5.734539
Free Cashflow -1,603,043
Full Exchange Name NasdaqGM
Full Time Employees 5
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits 0
Has Pre Post Market Data 1
Held Percent Insiders 0.5849
Held Percent Institutions 0.11769
Implied Shares Outstanding 25,931,865
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,025-03-26
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Long Name NeOnc Technologies Holdings, Inc.
Market us_market
Market Cap 112,025,656
Market State PRE
Max Age 86,400
Message Board Id finmb_1847121177
Most Recent Quarter 1,774,915,200
Net Income To Common -38,640,128
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 112,284,975
Number Of Analyst Opinions 3
Open 4.58
Operating Cashflow -21,705,666
Operating Margins 0.0
Payout Ratio 0.0
Phone 310 663 7831
Previous Close 4.49
Price Eps Current Year -5.082353
Price Hint 4
Price To Book -7.883212
Price To Sales Trailing12 Months Infinity
Profit Margins 0.0
Quick Ratio 0.017
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.17
Regular Market Change Percent -3.78618
Regular Market Day High 4.59
Regular Market Day Low 4.31
Regular Market Day Range 4.31 - 4.59
Regular Market Open 4.58
Regular Market Previous Close 4.49
Regular Market Price 4.32
Regular Market Time 1,783,972,800
Regular Market Volume 69,040
Return On Assets -3.5460901
Revenue Per Share 0.0
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 25,931,865
Shares Percent Shares Out 0.0150999995
Shares Short 391,112
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 268,593
Short Name NeOnc Technologies Holdings, In
Short Percent Of Float 0.0361
Short Ratio 3.46
Source Interval 15
State CA
Symbol NTHI
Target High Price 20.0
Target Low Price 13.0
Target Mean Price 16.0
Target Median Price 15.0
Total Cash 138,601
Total Cash Per Share 0.005
Total Debt 346,053
Total Revenue 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.73
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.79034
Two Hundred Day Average Change -3.4703398
Two Hundred Day Average Change Percent -0.44546705
Type Disp Equity
Volume 69,040
Website https://www.neonc.com
Zip 91,302